Educational only. Not medical advice. Invite-only research preview.No PHI. Do not share patient names or identifying information (HIPAA).
MytoIntelligence
All targets

Molecular target

CB2 Cannabinoid Receptor

Also: CNR2 · id CB2

Primarily peripheral and immune-cell cannabinoid receptor; mediates anti-inflammatory and immunomodulatory effects without psychoactivity.

2 drugs act here4 plants reach it via their compounds

Educational use only. This page summarizes published research and traditional-use records for educational purposes. It does not diagnose, treat, cure, or prevent any disease. Do not start, stop, or change medications based on this information. Discuss any decisions about therapies — pharmaceutical or botanical — with a qualified clinician who knows your medical history.

No PHI / HIPAA notice: Do not share Protected Health Information (PHI) of any patient on this site — including names, dates of birth, addresses, MRNs, or any identifying information. Use abstract case framing only. Sharing PHI with non-covered entities risks HIPAA violation regardless of platform capability.

Pharmaceutical agents

Drugs that act on CB2 Cannabinoid Receptor

These medications have CB2 Cannabinoid Receptor among their molecular targets. Sharing a target is a mechanistic relationship — it does not make any plant below an alternative to, or substitute for, these drugs.

Botanical connections

Plants whose compounds act on CB2 Cannabinoid Receptor

Each plant below contains a named compound documented to act on CB2 Cannabinoid Receptor. The compound and the reason for the connection are shown on every edge — a shared mechanism, not a therapeutic equivalence.

  • Δ9-Tetrahydrocannabinol (THC)Psychoactive cannabinoid

    Partial agonist at CB1 (psychoactivity, analgesia, appetite, memory effects) and CB2 (anti-inflammatory, immune).

  • Cannabigerol (CBG)Cannabinoid (parent)

    Precursor cannabinoid with weak CB1/CB2 partial agonism and α2-adrenergic activity. Lower psychoactivity than THC.

  • Cannabinol (CBN)Cannabinoid (degradation)

    Degradation product of THC; weak CB2 binding contributes to its sedative reputation.

  • β-CaryophylleneTerpene

    Selective CB2 agonist also found in many other plants (black pepper, clove); contributes to anti-inflammatory effects without psychoactivity.

  • β-caryophylleneSesquiterpene

    β-caryophyllene is a selective CB2 receptor agonist; preclinical studies report associated modulation of NF-κB signalling and reduction of COX-2-mediated prostaglandin synthesis. Cited mechanistic studies investigate this as a basis for the oleoresin's reported anti-inflammatory activity.

  • β-CaryophylleneSesquiterpene

    Preclinical evidence suggests selective CB2 agonism with downstream attenuation of NF-κB and TNF-α; proposed to contribute to anti-inflammatory activity.

  • AlkamidesFatty acid amide

    Lipophilic alkamides bind CB2 receptors — overlap with cannabis's anti-inflammatory pathway. Believed to be the primary immunomodulatory compounds.

A shared molecular target shows how a botanical and a drug relate mechanistically. It is not evidence that one can replace the other. Educational summary only — discuss any medication decision with your clinician.